US Stock MarketDetailed Quotes
SLXN Silexion Therapeutics
- 1.100
- -0.360-24.66%
Close Sep 3 16:00 ET
- 1.090
- -0.010-0.91%
Post 20:02 ET
8.58MMarket Cap-632P/E (TTM)
1.435High1.000Low725.49KVolume1.420Open1.460Pre Close823.91KTurnover39.00%Turnover RatioLossP/E (Static)7.80MShares13.55852wk High-1.70P/B2.05MFloat Cap1.00052wk Low--Dividend TTM1.86MShs Float13.558Historical High--Div YieldTTM29.80%Amplitude1.000Historical Low1.135Avg Price1Lot Size
Silexion Therapeutics Key Stats
Quarterly+Annual
YOY
| (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | |
|---|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating revenue | --0 | --0 | --0 | --0 | --0 | --0 |
| Cost of revenue | ||||||
| Gross profit | ||||||
| Operating expense | -2.05%1.39M | 54.70%1.25M | 21.27%4.68M | 1.41M | 808K | 3.86M |
| Selling and administrative expenses | 270.91%612K | 150.89%281K | 60.83%928K | --165K | --112K | --577K |
| -General and administrative expense | 270.91%612K | 150.89%281K | 60.83%928K | --165K | --112K | --577K |
| Research and development costs | -37.98%766K | 41.12%961K | 14.94%3.71M | --1.24M | --681K | --3.23M |
| Depreciation amortization depletion | -50.00%7K | -46.67%8K | -21.05%45K | --14K | --15K | --57K |
| -Depreciation and amortization | -50.00%7K | -46.67%8K | -21.05%45K | --14K | --15K | --57K |
| Operating profit | 2.05%-1.39M | -54.70%-1.25M | -21.27%-4.68M | -1.41M | -808K | -3.86M |
| Net non-operating interest income expense | -87.88%4K | -50.00%19K | 396.55%144K | 33K | 38K | 29K |
| Non-operating interest income | -84.62%6K | -51.28%19K | 34.21%153K | --39K | --39K | --114K |
| Non-operating interest expense | -33.33%2K | ---- | ---- | --3K | ---- | ---- |
| Total other finance cost | ---- | ---- | -89.41%9K | --3K | --1K | --85K |
| Other net income (expense) | 78.14%-106K | -605.41%-187K | -246.87%-539K | -485K | 37K | 367K |
| Gain on sale of security | 78.14%-106K | -605.41%-187K | -246.87%-539K | ---485K | --37K | --367K |
| Income before tax | 20.31%-1.49M | -93.45%-1.42M | -46.54%-5.08M | -1.87M | -733K | -3.46M |
| Income tax | -80.00%2K | -50.00%5K | 33.33%32K | 10K | 10K | 24K |
| Net income | 20.63%-1.49M | -91.52%-1.42M | -46.44%-5.11M | -1.88M | -743K | -3.49M |
| Net income continuous Operations | 20.63%-1.49M | -91.52%-1.42M | -46.44%-5.11M | ---1.88M | ---743K | ---3.49M |
| Minority interest income | 92.38%-17K | -261.29%-50K | 39.19%-166K | -223K | 31K | -273K |
| Net income attributable to the parent company | 10.95%-1.47M | -77.39%-1.37M | -53.72%-4.94M | -1.65M | -774K | -3.22M |
| Preferred stock dividends | ||||||
| Other preferred stock dividends | ||||||
| Net income attributable to common stockholders | 10.95%-1.47M | -77.39%-1.37M | -53.72%-4.94M | -1.65M | -774K | -3.22M |
| Basic earnings per share | 10.95%-0.1806 | -77.39%-0.1684 | -53.72%-0.6063 | -0.2028 | -0.095 | -0.3944 |
| Diluted earnings per share | 10.95%-0.1806 | -77.39%-0.1684 | -53.72%-0.6063 | -0.2028 | -0.095 | -0.3944 |
| Dividend per share | ||||||
| Currency Unit | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg